Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
Portfolio Pulse from Juan Spínelli
The global psychedelic drugs market is expected to grow by $1.37 billion from 2024 to 2028, driven by mental health disorders and AI integration. Key players include AbbVie, ATAI Life Sciences, COMPASS Pathways, Johnson & Johnson, Pfizer, and Mind Medicine. Despite growth potential, regulatory challenges and ethical concerns remain.
September 05, 2024 | 4:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie is a key player in the growing psychedelic drugs market, which is projected to expand by $1.37 billion by 2028. The company's involvement in developing psychedelic therapies positions it well for future growth.
AbbVie's involvement in psychedelic therapies aligns with the market's projected growth, suggesting potential positive impact on its stock.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 70
POSITIVE IMPACT
ATAI Life Sciences is at the forefront of psychedelic drug development, benefiting from the market's projected $1.37 billion growth by 2028. The company's focus on mental health therapies aligns with market trends.
ATAI's focus on psychedelic therapies for mental health positions it to benefit from the market's growth, likely boosting its stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 80
POSITIVE IMPACT
COMPASS Pathways is a major player in the psychedelic drugs market, which is expected to grow by $1.37 billion by 2028. The company's innovations in mental health therapies are well-aligned with market trends.
COMPASS Pathways' focus on innovative mental health therapies aligns with market growth, suggesting a positive impact on its stock.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 75
POSITIVE IMPACT
Johnson & Johnson is involved in the psychedelic drugs market, which is projected to grow by $1.37 billion by 2028. The company's role in developing therapies for mental health conditions aligns with market expansion.
Johnson & Johnson's involvement in psychedelic therapies for mental health could benefit from market growth, potentially impacting its stock positively.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 60
POSITIVE IMPACT
Mind Medicine is at the forefront of the psychedelic drugs market, projected to grow by $1.37 billion by 2028. The company's focus on mental health therapies aligns with market trends.
Mind Medicine's focus on psychedelic therapies for mental health positions it to benefit from market growth, likely boosting its stock.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 85
POSITIVE IMPACT
Pfizer is a key player in the psychedelic drugs market, expected to grow by $1.37 billion by 2028. The company's involvement in mental health therapies positions it for potential growth.
Pfizer's role in developing psychedelic therapies aligns with market growth, suggesting a positive impact on its stock.
CONFIDENCE 80
IMPORTANCE 65
RELEVANCE 65